Clinical Trial Update: Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Extension study up to 3 years for secukinumab in psoriatic arthritis completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-06-12